UnknownNot applicableNCT03184597

HLA Screening in Reducing the Risk of Antiepileptic Drug-induced Cutaneous Adverse Reactions

Studying Epilepsy syndrome

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Second Affiliated Hospital of Guangzhou Medical University
Principal Investigator
Wei-Ping Liao, M.D.,Ph.D.
Second Affiliated Hospital of Guangzhou Medical University
Intervention
HLA screening before commencing aromatic AEDs(diagnostic_test)
Enrollment
4000 enrolled
Eligibility
All sexes
Timeline
2017 – 2021

Study locations (1)

Collaborators

Guangzhou First People's Hospital · West China Hospital · Guangdong Provincial People's Hospital · First Affiliated Hospital of Jinan University · Guangdong 999 Brain Hospital · First Affiliated Hospital, Sun Yat-Sen University · Wuhan Women and Children's Medical Center · First People's Hospital, Shunde China

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03184597 on ClinicalTrials.gov

Other trials for Epilepsy syndrome

Additional recruiting or active studies for the same condition.

See all trials for Epilepsy syndrome →

← Back to all trials